Jump to content

CD154

From Wikipedia, the free encyclopedia
(Redirected from Cd40 ligand)

CD40LG
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesCD40LG, CD154, CD40L, HIGM1, IGM, IMD3, T-BAM, TNFSF5, TRAP, gp39, hCD40L, CD40 ligand
External IDsOMIM: 300386; MGI: 88337; HomoloGene: 56; GeneCards: CD40LG; OMA:CD40LG - orthologs
Orthologs
SpeciesHumanMouse
Entrez

959

21947

Ensembl

ENSG00000102245

ENSMUSG00000031132

UniProt

P29965

P27548

RefSeq (mRNA)

NM_000074

NM_011616

RefSeq (protein)

NP_000065

NP_035746

Location (UCSC)Chr X: 136.65 – 136.66 MbChr X: 56.26 – 56.27 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

CD154, also called CD40 ligand or CD40L, is a protein that is primarily expressed on activated T cells[5] and is a member of the TNF superfamily of molecules. It binds to CD40 on antigen-presenting cells (APC), which leads to many effects depending on the target cell type. In total CD40L has three binding partners: CD40, α5β1 integrin and integrin αIIbβ3. CD154 acts as a costimulatory molecule and is particularly important on a subset of T cells called T follicular helper cells (TFH cells).[6] On TFH cells, CD154 promotes B cell maturation and function by engaging CD40 on the B cell surface and therefore facilitating cell-cell communication.[7] A defect in this gene results in an inability to undergo immunoglobulin class switching and is associated with hyper IgM syndrome.[8] Absence of CD154 also stops the formation of germinal centers and therefore prohibiting antibody affinity maturation, an important process in the adaptive immune system.

History

[edit]

In 1991, three groups reported discovering CD154. Seth Lederman, Michael Yellin, and Leonard Chess at Columbia University generated a murine monoclonal antibody, 5c8, that inhibited contact-dependent T cell helper function in human cells and which characterized a 32 kDa surface protein transiently expressed on activated CD4+ T cells.[9] Richard Armitage at Immunex cloned a cDNA encoding CD154 by screening an expression library with CD40-Ig.[10] Randolph Noelle at Dartmouth Medical School generated an antibody that bound a 39 kDa protein on murine T cells and inhibited helper function.[11] Noelle contested Lederman's patent, but the challenge (called an interference) was rejected on all counts [12]

Expression

[edit]

CD40 ligand (CD154) is primarily expressed on activated CD4+ T lymphocytes but is also found in a soluble form. While CD40L was originally described on T lymphocytes, its expression has since been found on a wide variety of cells, including platelets, mast cells, macrophages, basophils, NK cells, B lymphocytes, as well as non-haematopoietic cells (smooth muscle cells, endothelial cells, and epithelial cells).[13]

Specific effects on cells

[edit]

CD40L plays a central role in costimulation and regulation of the immune response via T cell priming and activation of CD40-expressing immune cells.[14] At least 46 disease-causing mutations in this gene have been discovered.[15]

Macrophages

[edit]

In the macrophage, the primary signal for activation is IFN-γ from Th1 type CD4 T cells. The secondary signal is CD40L on the T cell, which binds CD40 on the macrophage cell surface. As a result, the macrophage expresses more CD40 and TNF receptors on its surface, which helps increase the level of activation. The activated macrophage can then destroy phagocytosed bacteria and produce more cytokines.

B cells

[edit]
T cell-dependent B cell activation, showing a TH2-cell (left), B cell (right), and several interaction molecules, the TH2-cell expressing CD40L.

B cells can present antigens to a specialized group of helper T cells called TFH cells. If an activated TFH cell recognizes the peptide presented by the B cell, the CD40L on the T cell binds to the B cell's CD40, causing B cell activation.[16] The T cell also produces IL-4, which directly influences B cells. As a result of this stimulation, the B cell can undergo rapid cellular division to form a germinal center where antibody isotype switching and affinity maturation occurs, as well as their differentiation to plasma cells and memory B cells. The end-result is a B cell that is able to mass-produce specific antibodies against an antigenic target. Early evidence for these effects were that in CD40 or CD154 deficient mice, there is little class switching or germinal centre formation, and immune responses are severely inhibited.[17]

Endothelial cells

[edit]

Activation of endothelial cells by CD40L (e.g. from activated platelets) leads to reactive oxygen species production, as well as chemokine and cytokine production, and expression of adhesion molecules such as E-selectin, ICAM-1, and VCAM-1. This inflammatory reaction in endothelial cells promotes recruitment of leukocytes to lesions and may potentially promote atherogenesis.[18] CD40L has shown to be a potential biomarker for atherosclerotic instability.[19]

Interactions

[edit]

CD154 has been shown to interact with RNF128.[20]

References

[edit]
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000102245 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000031132 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Lederman S, Yellin MJ, Krichevsky A, Belko J, Lee JJ, Chess L (April 1992). "Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (help)". The Journal of Experimental Medicine. 175 (4): 1091–1101. doi:10.1084/jem.175.4.1091. PMC 2119166. PMID 1348081.
  6. ^ Lederman S, Yellin MJ, Inghirami G, Lee JJ, Knowles DM, Chess L (December 1992). "Molecular interactions mediating T-B lymphocyte collaboration in human lymphoid follicles. Roles of T cell-B-cell-activating molecule (5c8 antigen) and CD40 in contact-dependent help". Journal of Immunology. 149 (12): 3817–3826. doi:10.4049/jimmunol.149.12.3817. PMID 1281189.
  7. ^ Lederman S, Yellin MJ, Cleary AM, Pernis A, Inghirami G, Cohn LE, et al. (March 1994). "T-BAM/CD40-L on helper T lymphocytes augments lymphokine-induced B cell Ig isotype switch recombination and rescues B cells from programmed cell death". Journal of Immunology. 152 (5): 2163–2171. doi:10.4049/jimmunol.152.5.2163. PMID 7907632. S2CID 42460521.
  8. ^ "Entrez Gene: CD40LG CD40 ligand (TNF superfamily, member 5, hyper-IgM syndrome)".
  9. ^ Lederman S, Yellin MJ, Krichevsky A, Belko J, Lee JJ, Chess L (April 1992). "Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (help)". The Journal of Experimental Medicine. 175 (4): 1091–1101. doi:10.1084/jem.175.4.1091. PMC 2119166. PMID 1348081.
  10. ^ Armitage RJ, Fanslow WC, Strockbine L, Sato TA, Clifford KN, Macduff BM, et al. (May 1992). "Molecular and biological characterization of a murine ligand for CD40". Nature. 357 (6373): 80–82. Bibcode:1992Natur.357...80A. doi:10.1038/357080a0. PMID 1374165. S2CID 4336943.
  11. ^ Noelle RJ, Roy M, Shepherd DM, Stamenkovic I, Ledbetter JA, Aruffo A (July 1992). "A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells". Proceedings of the National Academy of Sciences of the United States of America. 89 (14): 6550–6554. Bibcode:1992PNAS...89.6550N. doi:10.1073/pnas.89.14.6550. PMC 49539. PMID 1378631.
  12. ^ "Patent 5,474,771" (PDF). UNITED STATES PATENT AND TRADEMARK OFFICE. U.S. Patent Office. Archived from the original (PDF) on 2016-03-04. Retrieved 2016-06-18.
  13. ^ Schönbeck U, Libby P (January 2001). "The CD40/CD154 receptor/ligand dyad". Cellular and Molecular Life Sciences. 58 (1): 4–43. doi:10.1007/PL00000776. PMC 11146501. PMID 11229815. S2CID 33085593.
  14. ^ Grewal IS, Flavell RA (1998). "CD40 and CD154 in cell-mediated immunity". Annual Review of Immunology. 16: 111–135. doi:10.1146/annurev.immunol.16.1.111. PMID 9597126.
  15. ^ Šimčíková D, Heneberg P (December 2019). "Refinement of evolutionary medicine predictions based on clinical evidence for the manifestations of Mendelian diseases". Scientific Reports. 9 (1): 18577. Bibcode:2019NatSR...918577S. doi:10.1038/s41598-019-54976-4. PMC 6901466. PMID 31819097.
  16. ^ Cleary AM, Fortune SM, Yellin MJ, Chess L, Lederman S (October 1995). "Opposing roles of CD95 (Fas/APO-1) and CD40 in the death and rescue of human low density tonsillar B cells". Journal of Immunology. 155 (7): 3329–3337. doi:10.4049/jimmunol.155.7.3329. PMID 7561026. S2CID 39514335.
  17. ^ Grewal IS, Xu J, Flavell RA (December 1995). "Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand". Nature. 378 (6557): 617–620. Bibcode:1995Natur.378..617G. doi:10.1038/378617a0. PMID 8524395. S2CID 4259617.
  18. ^ Szmitko PE, Wang CH, Weisel RD, de Almeida JR, Anderson TJ, Verma S (October 2003). "New markers of inflammation and endothelial cell activation: Part I". Circulation. 108 (16): 1917–1923. doi:10.1161/01.CIR.0000089190.95415.9F. PMID 14568885.
  19. ^ Wang JH, Zhang YW, Zhang P, Deng BQ, Ding S, Wang ZK, et al. (September 2013). "CD40 ligand as a potential biomarker for atherosclerotic instability". Neurological Research. 35 (7): 693–700. doi:10.1179/1743132813Y.0000000190. PMC 3770830. PMID 23561892.
  20. ^ Lineberry NB, Su LL, Lin JT, Coffey GP, Seroogy CM, Fathman CG (August 2008). "Cutting edge: The transmembrane E3 ligase GRAIL ubiquitinates the costimulatory molecule CD40 ligand during the induction of T cell anergy". Journal of Immunology. 181 (3): 1622–1626. doi:10.4049/jimmunol.181.3.1622. PMC 2853377. PMID 18641297.

Further reading

[edit]
[edit]
Retrieved from "https://wiki.riteme.site/w/index.php?title=CD154&oldid=1251234820"